- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
As the global economy mends, the 2021 growth of Opioid-Induced Constipation will have significant change from previous year. According to our latest study, the global Opioid-Induced Constipation market size is USD million in 2022 from USD 2476 million in 2021, with a change of % between 2021 and 2022. The global Opioid-Induced Constipation market size will reach USD 3431.3 million in 2028, growing at a CAGR of 4.8% over the analysis period.
The United States Opioid-Induced Constipation market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Opioid-Induced Constipation market, reaching US$ million by the year 2028. As for the Europe Opioid-Induced Constipation landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Opioid-Induced Constipation players cover Takeda Pharmaceuticals, Bayer, Sanofi, and Mallinckrodt, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital
Pharmacy
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Opioid-Induced Constipation Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Opioid-Induced Constipation by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Opioid-Induced Constipation by Country/Region, 2017, 2022 & 2028
2.2 Opioid-Induced Constipation Segment by Type
2.2.1 Methylnaltrexone Bromide
2.2.2 Lubiprostone
2.2.3 Naloxegol
2.2.4 Others
2.3 Opioid-Induced Constipation Sales by Type
2.3.1 Global Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2017-2022)
2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2017-2022)
2.4 Opioid-Induced Constipation Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Opioid-Induced Constipation Sales by Application
2.5.1 Global Opioid-Induced Constipation Sale Market Share by Application (2017-2022)
2.5.2 Global Opioid-Induced Constipation Revenue and Market Share by Application (2017-2022)
2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2017-2022)
3 Global Opioid-Induced Constipation by Company
3.1 Global Opioid-Induced Constipation Breakdown Data by Company
3.1.1 Global Opioid-Induced Constipation Annual Sales by Company (2020-2022)
3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company (2020-2022)
3.2 Global Opioid-Induced Constipation Annual Revenue by Company (2020-2022)
3.2.1 Global Opioid-Induced Constipation Revenue by Company (2020-2022)
3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2022)
3.3 Global Opioid-Induced Constipation Sale Price by Company
3.4 Key Manufacturers Opioid-Induced Constipation Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Opioid-Induced Constipation Product Location Distribution
3.4.2 Players Opioid-Induced Constipation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Opioid-Induced Constipation by Geographic Region
4.1 World Historic Opioid-Induced Constipation Market Size by Geographic Region (2017-2022)
4.1.1 Global Opioid-Induced Constipation Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Opioid-Induced Constipation Annual Revenue by Geographic Region
4.2 World Historic Opioid-Induced Constipation Market Size by Country/Region (2017-2022)
4.2.1 Global Opioid-Induced Constipation Annual Sales by Country/Region (2017-2022)
4.2.2 Global Opioid-Induced Constipation Annual Revenue by Country/Region
4.3 Americas Opioid-Induced Constipation Sales Growth
4.4 APAC Opioid-Induced Constipation Sales Growth
4.5 Europe Opioid-Induced Constipation Sales Growth
4.6 Middle East & Africa Opioid-Induced Constipation Sales Growth
5 Americas
5.1 Americas Opioid-Induced Constipation Sales by Country
5.1.1 Americas Opioid-Induced Constipation Sales by Country (2017-2022)
5.1.2 Americas Opioid-Induced Constipation Revenue by Country (2017-2022)
5.2 Americas Opioid-Induced Constipation Sales by Type
5.3 Americas Opioid-Induced Constipation Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Opioid-Induced Constipation Sales by Region
6.1.1 APAC Opioid-Induced Constipation Sales by Region (2017-2022)
6.1.2 APAC Opioid-Induced Constipation Revenue by Region (2017-2022)
6.2 APAC Opioid-Induced Constipation Sales by Type
6.3 APAC Opioid-Induced Constipation Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Opioid-Induced Constipation by Country
7.1.1 Europe Opioid-Induced Constipation Sales by Country (2017-2022)
7.1.2 Europe Opioid-Induced Constipation Revenue by Country (2017-2022)
7.2 Europe Opioid-Induced Constipation Sales by Type
7.3 Europe Opioid-Induced Constipation Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Opioid-Induced Constipation by Country
8.1.1 Middle East & Africa Opioid-Induced Constipation Sales by Country (2017-2022)
8.1.2 Middle East & Africa Opioid-Induced Constipation Revenue by Country (2017-2022)
8.2 Middle East & Africa Opioid-Induced Constipation Sales by Type
8.3 Middle East & Africa Opioid-Induced Constipation Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Opioid-Induced Constipation
10.3 Manufacturing Process Analysis of Opioid-Induced Constipation
10.4 Industry Chain Structure of Opioid-Induced Constipation
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Opioid-Induced Constipation Distributors
11.3 Opioid-Induced Constipation Customer
12 World Forecast Review for Opioid-Induced Constipation by Geographic Region
12.1 Global Opioid-Induced Constipation Market Size Forecast by Region
12.1.1 Global Opioid-Induced Constipation Forecast by Region (2023-2028)
12.1.2 Global Opioid-Induced Constipation Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Opioid-Induced Constipation Forecast by Type
12.7 Global Opioid-Induced Constipation Forecast by Application
13 Key Players Analysis
13.1 Takeda Pharmaceuticals
13.1.1 Takeda Pharmaceuticals Company Information
13.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Offered
13.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Takeda Pharmaceuticals Main Business Overview
13.1.5 Takeda Pharmaceuticals Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Opioid-Induced Constipation Product Offered
13.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Opioid-Induced Constipation Product Offered
13.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Mallinckrodt
13.4.1 Mallinckrodt Company Information
13.4.2 Mallinckrodt Opioid-Induced Constipation Product Offered
13.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Mallinckrodt Main Business Overview
13.4.5 Mallinckrodt Latest Developments
13.5 Salix (Bausch Health)
13.5.1 Salix (Bausch Health) Company Information
13.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Offered
13.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Salix (Bausch Health) Main Business Overview
13.5.5 Salix (Bausch Health) Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Opioid-Induced Constipation Product Offered
13.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Progenics Pharmaceuticals
13.7.1 Progenics Pharmaceuticals Company Information
13.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Offered
13.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Progenics Pharmaceuticals Main Business Overview
13.7.5 Progenics Pharmaceuticals Latest Developments
13.8 Purdue Pharm
13.8.1 Purdue Pharm Company Information
13.8.2 Purdue Pharm Opioid-Induced Constipation Product Offered
13.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Purdue Pharm Main Business Overview
13.8.5 Purdue Pharm Latest Developments
13.9 Nektar Therapeutics
13.9.1 Nektar Therapeutics Company Information
13.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Offered
13.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Nektar Therapeutics Main Business Overview
13.9.5 Nektar Therapeutics Latest Developments
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Information
13.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Offered
13.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Daiichi Sankyo Main Business Overview
13.10.5 Daiichi Sankyo Latest Developments
13.11 Prestige
13.11.1 Prestige Company Information
13.11.2 Prestige Opioid-Induced Constipation Product Offered
13.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Prestige Main Business Overview
13.11.5 Prestige Latest Developments
13.12 GSK
13.12.1 GSK Company Information
13.12.2 GSK Opioid-Induced Constipation Product Offered
13.12.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 GSK Main Business Overview
13.12.5 GSK Latest Developments
13.13 Shionogi
13.13.1 Shionogi Company Information
13.13.2 Shionogi Opioid-Induced Constipation Product Offered
13.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Shionogi Main Business Overview
13.13.5 Shionogi Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Opioid-Induced Constipation Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Opioid-Induced Constipation Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Methylnaltrexone Bromide
Table 4. Major Players of Lubiprostone
Table 5. Major Players of Naloxegol
Table 6. Major Players of Others
Table 7. Global Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 8. Global Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
Table 9. Global Opioid-Induced Constipation Revenue by Type (2017-2022) & ($ million)
Table 10. Global Opioid-Induced Constipation Revenue Market Share by Type (2017-2022)
Table 11. Global Opioid-Induced Constipation Sale Price by Type (2017-2022) & (USD/Unit)
Table 12. Global Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 13. Global Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
Table 14. Global Opioid-Induced Constipation Revenue by Application (2017-2022)
Table 15. Global Opioid-Induced Constipation Revenue Market Share by Application (2017-2022)
Table 16. Global Opioid-Induced Constipation Sale Price by Application (2017-2022) & (USD/Unit)
Table 17. Global Opioid-Induced Constipation Sales by Company (2020-2022) & (K Units)
Table 18. Global Opioid-Induced Constipation Sales Market Share by Company (2020-2022)
Table 19. Global Opioid-Induced Constipation Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2022)
Table 21. Global Opioid-Induced Constipation Sale Price by Company (2020-2022) & (USD/Unit)
Table 22. Key Manufacturers Opioid-Induced Constipation Producing Area Distribution and Sales Area
Table 23. Players Opioid-Induced Constipation Products Offered
Table 24. Opioid-Induced Constipation Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Opioid-Induced Constipation Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global Opioid-Induced Constipation Sales Market Share Geographic Region (2017-2022)
Table 29. Global Opioid-Induced Constipation Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Opioid-Induced Constipation Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global Opioid-Induced Constipation Sales Market Share by Country/Region (2017-2022)
Table 33. Global Opioid-Induced Constipation Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Opioid-Induced Constipation Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
Table 36. Americas Opioid-Induced Constipation Sales Market Share by Country (2017-2022)
Table 37. Americas Opioid-Induced Constipation Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Opioid-Induced Constipation Revenue Market Share by Country (2017-2022)
Table 39. Americas Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 40. Americas Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
Table 41. Americas Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 42. Americas Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
Table 43. APAC Opioid-Induced Constipation Sales by Region (2017-2022) & (K Units)
Table 44. APAC Opioid-Induced Constipation Sales Market Share by Region (2017-2022)
Table 45. APAC Opioid-Induced Constipation Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Opioid-Induced Constipation Revenue Market Share by Region (2017-2022)
Table 47. APAC Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 48. APAC Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
Table 49. APAC Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 50. APAC Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
Table 51. Europe Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
Table 52. Europe Opioid-Induced Constipation Sales Market Share by Country (2017-2022)
Table 53. Europe Opioid-Induced Constipation Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Opioid-Induced Constipation Revenue Market Share by Country (2017-2022)
Table 55. Europe Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 56. Europe Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
Table 57. Europe Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 58. Europe Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Opioid-Induced Constipation Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 64. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 66. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Opioid-Induced Constipation
Table 68. Key Market Challenges & Risks of Opioid-Induced Constipation
Table 69. Key Industry Trends of Opioid-Induced Constipation
Table 70. Opioid-Induced Constipation Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Opioid-Induced Constipation Distributors List
Table 73. Opioid-Induced Constipation Customer List
Table 74. Global Opioid-Induced Constipation Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global Opioid-Induced Constipation Sales Market Forecast by Region
Table 76. Global Opioid-Induced Constipation Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Opioid-Induced Constipation Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Opioid-Induced Constipation Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas Opioid-Induced Constipation Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Opioid-Induced Constipation Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC Opioid-Induced Constipation Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Opioid-Induced Constipation Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe Opioid-Induced Constipation Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Opioid-Induced Constipation Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa Opioid-Induced Constipation Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Opioid-Induced Constipation Sales Forecast by Type (2023-2028) & (K Units)
Table 87. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2023-2028)
Table 88. Global Opioid-Induced Constipation Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global Opioid-Induced Constipation Sales Forecast by Application (2023-2028) & (K Units)
Table 91. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2023-2028)
Table 92. Global Opioid-Induced Constipation Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2023-2028)
Table 94. Takeda Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 95. Takeda Pharmaceuticals Opioid-Induced Constipation Product Offered
Table 96. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 97. Takeda Pharmaceuticals Main Business
Table 98. Takeda Pharmaceuticals Latest Developments
Table 99. Bayer Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 100. Bayer Opioid-Induced Constipation Product Offered
Table 101. Bayer Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 102. Bayer Main Business
Table 103. Bayer Latest Developments
Table 104. Sanofi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 105. Sanofi Opioid-Induced Constipation Product Offered
Table 106. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 107. Sanofi Main Business
Table 108. Sanofi Latest Developments
Table 109. Mallinckrodt Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 110. Mallinckrodt Opioid-Induced Constipation Product Offered
Table 111. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 112. Mallinckrodt Main Business
Table 113. Mallinckrodt Latest Developments
Table 114. Salix (Bausch Health) Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 115. Salix (Bausch Health) Opioid-Induced Constipation Product Offered
Table 116. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 117. Salix (Bausch Health) Main Business
Table 118. Salix (Bausch Health) Latest Developments
Table 119. AstraZeneca Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 120. AstraZeneca Opioid-Induced Constipation Product Offered
Table 121. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 122. AstraZeneca Main Business
Table 123. AstraZeneca Latest Developments
Table 124. Progenics Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 125. Progenics Pharmaceuticals Opioid-Induced Constipation Product Offered
Table 126. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 127. Progenics Pharmaceuticals Main Business
Table 128. Progenics Pharmaceuticals Latest Developments
Table 129. Purdue Pharm Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 130. Purdue Pharm Opioid-Induced Constipation Product Offered
Table 131. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 132. Purdue Pharm Main Business
Table 133. Purdue Pharm Latest Developments
Table 134. Nektar Therapeutics Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 135. Nektar Therapeutics Opioid-Induced Constipation Product Offered
Table 136. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 137. Nektar Therapeutics Main Business
Table 138. Nektar Therapeutics Latest Developments
Table 139. Daiichi Sankyo Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 140. Daiichi Sankyo Opioid-Induced Constipation Product Offered
Table 141. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 142. Daiichi Sankyo Main Business
Table 143. Daiichi Sankyo Latest Developments
Table 144. Prestige Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 145. Prestige Opioid-Induced Constipation Product Offered
Table 146. Prestige Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 147. Prestige Main Business
Table 148. Prestige Latest Developments
Table 149. GSK Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 150. GSK Opioid-Induced Constipation Product Offered
Table 151. GSK Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 152. GSK Main Business
Table 153. GSK Latest Developments
Table 154. Shionogi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 155. Shionogi Opioid-Induced Constipation Product Offered
Table 156. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 157. Shionogi Main Business
Table 158. Shionogi Latest Developments
List of Figures
Figure 1. Picture of Opioid-Induced Constipation
Figure 2. Opioid-Induced Constipation Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Opioid-Induced Constipation Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Opioid-Induced Constipation Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Opioid-Induced Constipation Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Methylnaltrexone Bromide
Figure 10. Product Picture of Lubiprostone
Figure 11. Product Picture of Naloxegol
Figure 12. Product Picture of Others
Figure 13. Global Opioid-Induced Constipation Sales Market Share by Type in 2021
Figure 14. Global Opioid-Induced Constipation Revenue Market Share by Type (2017-2022)
Figure 15. Opioid-Induced Constipation Consumed in Hospital
Figure 16. Global Opioid-Induced Constipation Market: Hospital (2017-2022) & (K Units)
Figure 17. Opioid-Induced Constipation Consumed in Pharmacy
Figure 18. Global Opioid-Induced Constipation Market: Pharmacy (2017-2022) & (K Units)
Figure 19. Opioid-Induced Constipation Consumed in Other
Figure 20. Global Opioid-Induced Constipation Market: Other (2017-2022) & (K Units)
Figure 21. Global Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
Figure 22. Global Opioid-Induced Constipation Revenue Market Share by Application in 2021
Figure 23. Opioid-Induced Constipation Revenue Market by Company in 2021 ($ Million)
Figure 24. Global Opioid-Induced Constipation Revenue Market Share by Company in 2021
Figure 25. Global Opioid-Induced Constipation Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region in 2021
Figure 27. Global Opioid-Induced Constipation Sales Market Share by Region (2017-2022)
Figure 28. Global Opioid-Induced Constipation Revenue Market Share by Country/Region in 2021
Figure 29. Americas Opioid-Induced Constipation Sales 2017-2022 (K Units)
Figure 30. Americas Opioid-Induced Constipation Revenue 2017-2022 ($ Millions)
Figure 31. APAC Opioid-Induced Constipation Sales 2017-2022 (K Units)
Figure 32. APAC Opioid-Induced Constipation Revenue 2017-2022 ($ Millions)
Figure 33. Europe Opioid-Induced Constipation Sales 2017-2022 (K Units)
Figure 34. Europe Opioid-Induced Constipation Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa Opioid-Induced Constipation Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa Opioid-Induced Constipation Revenue 2017-2022 ($ Millions)
Figure 37. Americas Opioid-Induced Constipation Sales Market Share by Country in 2021
Figure 38. Americas Opioid-Induced Constipation Revenue Market Share by Country in 2021
Figure 39. United States Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC Opioid-Induced Constipation Sales Market Share by Region in 2021
Figure 44. APAC Opioid-Induced Constipation Revenue Market Share by Regions in 2021
Figure 45. China Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 49. India Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe Opioid-Induced Constipation Sales Market Share by Country in 2021
Figure 52. Europe Opioid-Induced Constipation Revenue Market Share by Country in 2021
Figure 53. Germany Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 54. France Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country in 2021
Figure 59. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country in 2021
Figure 60. Egypt Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of Opioid-Induced Constipation in 2021
Figure 66. Manufacturing Process Analysis of Opioid-Induced Constipation
Figure 67. Industry Chain Structure of Opioid-Induced Constipation
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
Please feel free to write an email to us or to use our electronic ticketing system.
